{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:41:36Z","timestamp":1793173296842,"version":"4.5.0"},"reference-count":129,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with \u03b2-thalassemia major (TM) and other refractory anemias requiring regular blood transfusions accumulate iron that damages the liver, endocrine system, and most importantly the heart. The prognosis in TM has improved remarkably over the past 10 years. This improvement has resulted from the development of magnetic resonance imaging (MRI) techniques, especially T2*, to accurately measure cardiac and liver iron, and from the availability of 3 iron-chelating drugs. In this article we describe the use of MRI to determine which adult and pediatric patients need to begin iron chelation therapy and to monitor their progress. We summarize the properties of each of the 3 drugs, deferoxamine (DFO), deferiprone (DFP), and deferasirox (DFX), including their efficacy, patient acceptability, and side effects. We describe when to initiate or intensify therapy, switch to another drug, or use combined therapy. We also discuss the management of refractory anemias other than TM that may require multiple blood transfusions, including sickle cell anemia and myelodysplasia. The development of a potential fourth chelator FBS 0701 and the combined use of oral chelators may further improve the quality of life and survival in patients with TM and other transfusion-dependent patients.<\/jats:p>","DOI":"10.1182\/blood-2012-05-370098","type":"journal-article","created":{"date-parts":[[2012,8,24]],"date-time":"2012-08-24T00:16:55Z","timestamp":1345767415000},"page":"3657-3669","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":156,"title":["How I treat transfusional iron overload"],"prefix":"10.1182","volume":"120","author":[{"given":"A. Victor","family":"Hoffbrand","sequence":"first","affiliation":[{"name":"Department of Haematology, University College London and Royal Free Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Taher","sequence":"additional","affiliation":[{"name":"Department of Medicine, American University of Beirut, Beirut, Lebanon; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Domenica","family":"Cappellini","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Polyclinico Ca Granda Istituto di Ricovero e Cura a Carattere Scientifico Foundation, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2019111808234862200_B1","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1629","article-title":"High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin.","volume":"13","author":"Tanno","year":"2007","journal-title":"Nat Med"},{"issue":"13","key":"2019111808234862200_B2","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1182\/blood-2010-08-300335","article-title":"How I treat thalassemia.","volume":"118","author":"Rachmilewitz","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111808234862200_B3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMct1004810","article-title":"Iron-chelating therapy for transfusional iron overload.","volume":"364","author":"Brittenham","year":"2011","journal-title":"N Engl J Med"},{"key":"2019111808234862200_B4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/asheducation-2011.1.451","article-title":"Real-world use of iron chelators.","volume":"2011","author":"Kwiatkowski","year":"2011","journal-title":"Hematology Am Soc Hematology Educ Program"},{"issue":"23","key":"2019111808234862200_B5","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1053\/euhj.2001.2822","article-title":"Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload.","volume":"22","author":"Anderson","year":"2001","journal-title":"Eur Heart J"},{"issue":"5","key":"2019111808234862200_B6","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1182\/blood-2003-06-1919","article-title":"Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease.","volume":"103","author":"Wood","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2019111808234862200_B7","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/jmri.20915","article-title":"Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron.","volume":"25","author":"Westwood","year":"2007","journal-title":"J Magn Reson Imaging"},{"issue":"9","key":"2019111808234862200_B8","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199409013310903","article-title":"Survival in medically treated patients with homozygous beta-thalassemia.","volume":"331","author":"Olivieri","year":"1994","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111808234862200_B9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000203853","article-title":"Results of long-term iron-chelating therapy.","volume":"95","author":"Gabutti","year":"1996","journal-title":"Acta Haematol"},{"issue":"4","key":"2019111808234862200_B10","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1046\/j.1365-2141.2000.02298.x","article-title":"Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major.","volume":"110","author":"Telfer","year":"2000","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111808234862200_B11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1182\/blood-2003-08-2841","article-title":"Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major.","volume":"104","author":"Davis","year":"2004","journal-title":"Blood"},{"issue":"20","key":"2019111808234862200_B12","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1161\/CIRCULATIONAHA.109.874487","article-title":"Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major.","volume":"120","author":"Kirk","year":"2009","journal-title":"Circulation"},{"issue":"5","key":"2019111808234862200_B13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJM200008033430503","article-title":"Hepatic iron concentration and total body iron stores in thalassemia major.","volume":"343","author":"Angelucci","year":"2000","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111808234862200_B14","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJM199409013310902","article-title":"Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major.","volume":"331","author":"Brittenham","year":"1994","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111808234862200_B15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2141.1995.tb08412.x","article-title":"Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies.","volume":"89","author":"Angelucci","year":"1995","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111808234862200_B16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2002-06-1704","article-title":"Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias.","volume":"101","author":"Jensen","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2019111808234862200_B17","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0168-8278(96)80070-5","article-title":"Variability in hepatic iron concentration measurement from needle-biopsy specimens.","volume":"25","author":"Villeneuve","year":"1996","journal-title":"J Hepatol"},{"issue":"4","key":"2019111808234862200_B18","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2004-10-3982","article-title":"MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients.","volume":"106","author":"Wood","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2019111808234862200_B19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/jmri.22245","article-title":"International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers.","volume":"32","author":"Kirk","year":"2010","journal-title":"J Magn Reson Imaging"},{"issue":"14","key":"2019111808234862200_B20","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.110.007641","article-title":"On T2* magnetic resonance and cardiac iron.","volume":"123","author":"Carpenter","year":"2011","journal-title":"Circulation"},{"key":"2019111808234862200_B21","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S0268-960X(08)70004-3","article-title":"Cardiac iron across different transfusion-dependent diseases.","volume":"22","author":"Wood","year":"2008","journal-title":"Blood Rev"},{"issue":"13","key":"2019111808234862200_B22","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1093\/eurheartj\/ehq106","article-title":"Relation of myocardial T2* to right ventricular function in thalassaemia major.","volume":"31","author":"Alpendurada","year":"2010","journal-title":"Eur Heart J"},{"key":"2019111808234862200_B23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1532-429X-10-42","article-title":"Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance.","volume":"10","author":"Modell","year":"2008","journal-title":"J Cardiovasc Magn Reson"},{"issue":"3","key":"2019111808234862200_B24","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2141.2004.05202.x","article-title":"Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance.","volume":"127","author":"Anderson","year":"2004","journal-title":"Br J Haematol"},{"issue":"2-3","key":"2019111808234862200_B25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000243799","article-title":"Role of T2* magnetic resonance in monitoring iron chelation therapy.","volume":"122","author":"Carpenter","year":"2009","journal-title":"Acta Haematol"},{"issue":"7","key":"2019111808234862200_B26","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2008-04-148767","article-title":"Longitudinal analysis of heart and liver iron in thalassemia major.","volume":"112","author":"Noetzli","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111808234862200_B27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1182\/blood.V88.2.705.bloodjournal882705","article-title":"Kinetics of removal and reappearance of iron transferrin bound plasma iron with Desferioxamine therapy.","volume":"88","author":"Porter","year":"1996","journal-title":"Blood"},{"issue":"1","key":"2019111808234862200_B28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000089475","article-title":"Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine.","volume":"115","author":"Anderson","year":"2006","journal-title":"Acta Haematol"},{"issue":"3","key":"2019111808234862200_B29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/10976640600698155","article-title":"Myocardial iron loading in patients with thalassemia major on deferoxamine chelation.","volume":"8","author":"Tanner","year":"2006","journal-title":"Cardiovasc Magn Reson"},{"issue":"2","key":"2019111808234862200_B30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/beha.2002.0214","article-title":"Monitoring chelation therapy to achieve optimal outcome in treatment of thalassemia.","volume":"15","author":"Porter","year":"2002","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"2019111808234862200_B31","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3324\/haematol.12413","article-title":"Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.","volume":"93","author":"Angelucci","year":"2008","journal-title":"Haematologica"},{"issue":"3","key":"2019111808234862200_B32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2141.1989.tb07761.x","article-title":"Desferrioxamine ototoxicity: evaluation of risk factors in thalassemic patients and guidelines for safe dosage.","volume":"73","author":"Porter","year":"1989","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111808234862200_B33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2002-06-1867","article-title":"Role of deferiprone in chelation therapy for transfusional iron overload.","volume":"102","author":"Hoffbrand","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2019111808234862200_B34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1046\/j.1365-2141.1998.01002.x","article-title":"Combined therapy with deferiprone and desferioxamine.","volume":"103","author":"Wonke","year":"1998","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111808234862200_B35","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000087888","article-title":"Safety and effectiveness of 100 mg\/kg\/day deferiprone in patients with thalassaemia major: a two year study.","volume":"114","author":"Taher","year":"2005","journal-title":"Acta Haematol"},{"issue":"9","key":"2019111808234862200_B36","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1182\/blood-2005-02-0460","article-title":"Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells.","volume":"106","author":"Glickstein","year":"2005","journal-title":"Blood"},{"issue":"9","key":"2019111808234862200_B37","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2005-07-2933","article-title":"Cardiac morbidity and mortality in deferoxamine or deferiprone treated patients with thalassaemia major.","volume":"107","author":"Borgna-Pignatti","year":"2006","journal-title":"Blood"},{"issue":"9332","key":"2019111808234862200_B38","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(02)09740-4","article-title":"Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.","volume":"360","author":"Anderson","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"2019111808234862200_B39","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/bcmd.2002.0510","article-title":"Deferiprone versus deferoxamine in patients with thalassaemia major: a randomized clinical trial.","volume":"28","author":"Maggio","year":"2002","journal-title":"Blood Cells Mol Dis"},{"issue":"5","key":"2019111808234862200_B40","first-page":"489","article-title":"Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassaemia major: a retrospective analysis.","volume":"88","author":"Piga","year":"2003","journal-title":"Haematologica"},{"issue":"1","key":"2019111808234862200_B41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.2009.019042","article-title":"Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.","volume":"96","author":"Pepe","year":"2011","journal-title":"Haematologica"},{"issue":"9","key":"2019111808234862200_B42","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","article-title":"Randomized controlled trial deferiprone or deferoxamine in beta-thalassaemia major patients with asymptomatic myocardial siderosis.","volume":"107","author":"Pennell","year":"2006","journal-title":"Blood"},{"issue":"3","key":"2019111808234862200_B43","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bcmd.2009.01.002","article-title":"Improving survival with deferiprone treatment in patients with thalassaemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassaemia and Hemoglobinopathies.","volume":"42","author":"Maggio","year":"2009","journal-title":"Blood Cells Mol Dis"},{"issue":"5","key":"2019111808234862200_B44","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2002-10-3280","article-title":"Safety and effectiveness of long term therapy with the oral iron chelator deferiprone.","volume":"102","author":"Cohen","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2019111808234862200_B45","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1046\/j.1365-2141.2002.03554.x","article-title":"The safety and effectiveness of deferiprone in a large scale, 3 year study in Italian patients.","volume":"118","author":"Ceci","year":"2002","journal-title":"Br J Haematol"},{"issue":"8","key":"2019111808234862200_B46","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/MPH.0b013e3181ec0f13","article-title":"The safety, tolerability and efficacy of a liquid formulation of Deferiprone in young children with transfusional iron overload.","volume":"32","author":"Elalfy","year":"2010","journal-title":"J. Pediatr Hemat Oncol"},{"issue":"8600","key":"2019111808234862200_B47","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(89)90641-7","article-title":"Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial.","volume":"2","author":"Hoffbrand","year":"1989","journal-title":"Lancet"},{"issue":"12","key":"2019111808234862200_B48","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1182\/blood-2007-02-065805","article-title":"Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia.","volume":"109","author":"Henter","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2019111808234862200_B49","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/jcp.47.7.657","article-title":"Zinc concentration in patients with iron overload receiving iron chelated 1,2-dimethyl-3-hydroxy-4-one or deferoxamine.","volume":"47","author":"Al-Refai","year":"1994","journal-title":"J Clin Pathol"},{"issue":"4","key":"2019111808234862200_B50","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0037-1963(01)90030-7","article-title":"Chelation therapy in beta-thalassemia: an optimistic update.","volume":"38","author":"Giardina","year":"2001","journal-title":"Semin Hematol"},{"issue":"3","key":"2019111808234862200_B51","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1182\/blood.V97.3.792","article-title":"Deferoxamine: chelatable iron, a component of serum iron-transferrin-bound iron, used for assessing chelation therapy.","volume":"97","author":"Breuer","year":"2001","journal-title":"Blood"},{"issue":"2","key":"2019111808234862200_B52","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.trsl.2010.05.002","article-title":"Mechanisms for the shuttling of plasma non-transferrin bound iron (NTBI) onto deferoxamine by deferiprone.","volume":"156","author":"Evans","year":"2010","journal-title":"Transl Res"},{"issue":"2","key":"2019111808234862200_B53","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1042\/BJ20070823","article-title":"Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.","volume":"409","author":"Devanur","year":"2008","journal-title":"Biochem J"},{"key":"2019111808234862200_B54","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1749-6632.2010.05591.x","article-title":"Combined iron chelation therapy.","volume":"1202","author":"Galanello","year":"2010","journal-title":"Ann NY Acad Sci"},{"issue":"1","key":"2019111808234862200_B55","first-page":"21","article-title":"Comparative efficacy of Desferrioxamine, Deferiprone and in combination on iron chelation in thalassemic children.","volume":"41","author":"Gomber","year":"2004","journal-title":"Indian Pediatr"},{"issue":"114","key":"2019111808234862200_B56","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","article-title":"A randomized, placebo-controlled, double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.","volume":"115","author":"Tanner","year":"2007","journal-title":"Circulation"},{"key":"2019111808234862200_B57","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1532-429X-10-12","article-title":"Combined chelation therapy in thalassaemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.","volume":"10","author":"Tanner","year":"2008","journal-title":"J Cardiovasc Magn Reson"},{"key":"2019111808234862200_B58","first-page":"1187","article-title":"Survival of medically treated thalassaemia patients in Cyprus: trends and risk factors over the period 1980-2004.","volume":"91","author":"Telfer","year":"2006","journal-title":"Haematologica"},{"issue":"2","key":"2019111808234862200_B59","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2009.07609.x","article-title":"Long-term sequential deferiprone deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial.","volume":"145","author":"Maggio","year":"2009","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111808234862200_B60","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bcmd.2010.05.005","article-title":"Increased survival and reversion of iron induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.","volume":"45","author":"Lai","year":"2010","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"2019111808234862200_B61","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2141.2009.07970.x","article-title":"Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.","volume":"148","author":"Farmaki","year":"2010","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111808234862200_B62","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.bcmd.2011.07.002","article-title":"Iron chelation therapy in thalassaemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials.","volume":"47","author":"Maggio","year":"2011","journal-title":"Blood Cells Mol Dis"},{"issue":"9","key":"2019111808234862200_B63","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","article-title":"A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.","volume":"107","author":"Cappellini","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2019111808234862200_B64","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1600-0609.2009.01228.x","article-title":"Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.","volume":"82","author":"Taher","year":"2009","journal-title":"Eur J Haematol"},{"issue":"5","key":"2019111808234862200_B65","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2141.2009.07908.x","article-title":"Efficacy and safety of deferasirox doses of > 30 mg\/kg per d in patients with transfusion-dependent anaemia and iron overload.","volume":"147","author":"Taher","year":"2009","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111808234862200_B66","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2010-11-316646","article-title":"Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.","volume":"118","author":"Cappellini","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111808234862200_B67","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1053\/j.gastro.2011.06.065","article-title":"Improvement in liver pathology of patients with beta-thalassemia treated with deferasirox for at least 3 years.","volume":"141","author":"Deugnier","year":"2011","journal-title":"Gastroenterology"},{"issue":"4","key":"2019111808234862200_B68","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000313447","article-title":"Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-thalassemia: results from the ESCALATOR Trial.","volume":"123","author":"Taher","year":"2010","journal-title":"Acta Haematol"},{"issue":"4","key":"2019111808234862200_B69","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3324\/haematol.2009.014696","article-title":"Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.","volume":"95","author":"Cappellini","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"2019111808234862200_B70","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3324\/haematol.2010.031468","article-title":"Continued improvement in myocardial T2* over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload.","volume":"96","author":"Pennell","year":"2011","journal-title":"Haematologica"},{"issue":"12","key":"2019111808234862200_B71","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1182\/blood-2009-04-217455","article-title":"Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.","volume":"115","author":"Pennell","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111808234862200_B72","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3324\/haematol.2011.049957","article-title":"Deferasirox for up to 3 years leads to continued improvement in myocardial T2* in patients with beta-thalassemia major.","volume":"97","author":"Pennell","year":"2012","journal-title":"Haematologica"},{"issue":"4","key":"2019111808234862200_B73","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2009-11-250308","article-title":"The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores.","volume":"116","author":"Wood","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111808234862200_B74","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/pbc.22826","article-title":"Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent beta-thalassemia.","volume":"56","author":"Chang","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"2019111808234862200_B75","first-page":"5423","article-title":"Safety of deferasirox (Exjade) in patients with transfusion-dependent anemias and iron overload who achieve serum ferritin levels < 1000 ng\/ml during long-term treatment [abstract].","volume":"112","author":"Porter","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"3","key":"2019111808234862200_B76","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2141.2006.06455.x","article-title":"A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.","volume":"136","author":"Vichinsky","year":"2007","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111808234862200_B77","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2141.2011.08720.x","article-title":"Long term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron overloaded patients with sickle cell disease.","volume":"154","author":"Vichinsky","year":"2011","journal-title":"Br J Haematol"},{"issue":"14","key":"2019111808234862200_B78","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1182\/blood-2010-01-261289","article-title":"Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial.","volume":"116","author":"Lee","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2019111808234862200_B79","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.leukres.2010.03.009","article-title":"Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study.","volume":"34","author":"Gattermann","year":"2010","journal-title":"Leuk Res"},{"issue":"3","key":"2019111808234862200_B80","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1600-0609.2011.01726.x","article-title":"Deferasirox treatment of iron-overloaded chelation-naive and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.","volume":"88","author":"Gattermann","year":"2012","journal-title":"Eur J Haematol"},{"issue":"5","key":"2019111808234862200_B81","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ajh.21119","article-title":"Clinical application of deferasirox: practical patient management.","volume":"83","author":"Vichinsky","year":"2008","journal-title":"Am J Hematol"},{"key":"2019111808234862200_B82","first-page":"4269","article-title":"Combined chelation therapy with Deferasirox and Deferoxamine in transfusion dependent thalassemia [abstract].","volume":"116","author":"Lal","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"2","key":"2019111808234862200_B83","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000174757","article-title":"Safety and efficacy of combined chelation therapy with desferasirox and deferoxamine in a gerbil model of iron overload.","volume":"120","author":"Otto-Duessel","year":"2008","journal-title":"Acta Haematol"},{"issue":"5","key":"2019111808234862200_B84","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/MPH.0b013e3181e015b0","article-title":"Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years.","volume":"32","author":"Jetsrisuparb","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"2019111808234862200_B85","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.bcmd.2011.03.007","article-title":"Oral chelators in transfusion-dependent thalassemia may prevent or reverse iron overload complications.","volume":"47","author":"Farmaki","year":"2011","journal-title":"Blood Cells Mol Dis"},{"issue":"11","key":"2019111808234862200_B86","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-010-0933-1","article-title":"Combining two orally active chelators for thalassemia.","volume":"89","author":"Berdarkas","year":"2010","journal-title":"Ann Hematol"},{"issue":"5","key":"2019111808234862200_B87","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2141.2011.08626.x","article-title":"Successful chelation therapy with the combination of deferasirox and deferriprone in a patient with thalassemia and persisting iron overload after single agent chelation therapies.","volume":"154","author":"Voskaridou","year":"2011","journal-title":"Br J Haematol"},{"issue":"13","key":"2019111808234862200_B88","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1021\/jm800154m","article-title":"Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.","volume":"51","author":"Bergeron","year":"2008","journal-title":"J Med Chem"},{"issue":"4","key":"2019111808234862200_B89","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3324\/haematol.2010.034405","article-title":"A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload.","volume":"96","author":"Rienhoff","year":"2011","journal-title":"Haematologica"},{"issue":"14","key":"2019111808234862200_B90","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1182\/blood-2011-10-386268","article-title":"A phase 2 study of the safety, tolerability and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload.","volume":"119","author":"Neufeld","year":"2012","journal-title":"Blood"},{"key":"2019111808234862200_B91","volume-title":"Guidelines for the Clinical Management of Thalassemia","author":"Cappellini","year":"2009"},{"issue":"10","key":"2019111808234862200_B92","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ajh.21806","article-title":"Iron chelation therapy for patients with sickle cell disease and iron overload.","volume":"85","author":"Inati","year":"2010","journal-title":"Am J Hematol"},{"issue":"12","key":"2019111808234862200_B93","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1182\/blood-2011-04-344507","article-title":"Chelation use and iron burden in North America and British thalassemia patients: a report from the thalassemia longitudinal cohort.","volume":"119","author":"Kwiatkowski","year":"2012","journal-title":"Blood"},{"key":"2019111808234862200_B94","article-title":"Desferasirox-induced renal impairment in children: an increasing concern for pediatricians [published online ahead of print April 24, 2012].","author":"Dubourg","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"2019111808234862200_B95","first-page":"51","article-title":"Introduction.","volume":"26","author":"Taher","year":"2012","journal-title":"Blood Rev"},{"issue":"10","key":"2019111808234862200_B96","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.3324\/haematol.13098","article-title":"Correlations of liver iron concentration determined by R2 magentic resonance imaging with serum ferritin in paients with thalassemia intermedia.","volume":"93","author":"Taher","year":"2008","journal-title":"Haematologica"},{"issue":"5","key":"2019111808234862200_B97","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2141.2010.08346.x","article-title":"Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.","volume":"151","author":"Ladis","year":"2010","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111808234862200_B98","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.1365-2141.2003.04412.x","article-title":"Clinical trial of deferiprone iron chelation therapy in beta thalassaemia\/haemoglobin E patients in Thailand.","volume":"122","author":"Pootrakul","year":"2003","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111808234862200_B99","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2141.2009.07848.x","article-title":"Iron overload in thalassemia intermedia: reassessment of iron chelation strategies.","volume":"147","author":"Taher","year":"2009","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111808234862200_B100","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-2141.2009.07930.x","article-title":"Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassemia intermedia: results of a pilot study.","volume":"148","author":"Voskaridou","year":"2009","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111808234862200_B101","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood-2012-02-412692","article-title":"Deferasirox significantly reduces iron overload in non-transfusion-dependent thalassaemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.","volume":"120","author":"Taher","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2019111808234862200_B102","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1600-0609.2011.01660.x","article-title":"Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.","volume":"87","author":"Porter","year":"2011","journal-title":"Eur J Haematol"},{"issue":"1","key":"2019111808234862200_B103","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2141.2009.07842.x","article-title":"Guidelines for the diagnosis and management of aplastic anaemia.","volume":"147","author":"Marsh","year":"2009","journal-title":"Br J Haematol"},{"issue":"9757","key":"2019111808234862200_B104","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease.","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"2019111808234862200_B105","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.20685","article-title":"Circumstances of death in adult sickle cell disease patients.","volume":"81","author":"Darbari","year":"2006","journal-title":"Am J Hematol"},{"issue":"2","key":"2019111808234862200_B106","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3109\/08880018.2010.505506","article-title":"Transfusion and chelation practices in sickle cell disease: a regional perspective.","volume":"28","author":"Vichinsky","year":"2011","journal-title":"Pediatr Hematol Oncol"},{"issue":"6","key":"2019111808234862200_B107","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1600-0609.2009.01345.x","article-title":"Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease.","volume":"83","author":"Inati","year":"2009","journal-title":"Eur J Haematol"},{"issue":"4","key":"2019111808234862200_B108","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/ajh.20809","article-title":"Morbidity and mortality in chronically transfused subjects with thalassemia and sicke cell disease: a report from the multicentre study of iron overload.","volume":"82","author":"Fung","year":"2007","journal-title":"Am J Hematol"},{"issue":"5","key":"2019111808234862200_B109","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2141.2011.08769.x","article-title":"Chelation treatment in sickle cell anaemia: much ado about nothing?","volume":"154","author":"Lucania","year":"2011","journal-title":"Br J Haematol"},{"issue":"30","key":"2019111808234862200_B110","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","article-title":"Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.","volume":"23","author":"Malcovati","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111808234862200_B111","first-page":"1588","article-title":"Predicting survival and leukemic evolution in patients with myelodysplastic syndrome.","volume":"91","author":"Malcovati","year":"2006","journal-title":"Haematologica"},{"issue":"6","key":"2019111808234862200_B112","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1600-0609.2007.00842.x","article-title":"Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity\/mortality.","volume":"78","author":"Takatoku","year":"2007","journal-title":"Eur J Haematol"},{"issue":"3","key":"2019111808234862200_B113","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3324\/haematol.2009.011429","article-title":"Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study.","volume":"95","author":"Alessandrino","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"2019111808234862200_B114","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3324\/haematol.2009.017244","article-title":"Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation.","volume":"95","author":"Koreth","year":"2010","journal-title":"Haematologica"},{"issue":"5","key":"2019111808234862200_B115","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1634\/theoncologist.2008-0154","article-title":"Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.","volume":"14","author":"Jabbour","year":"2009","journal-title":"Oncologist"},{"issue":"26","key":"2019111808234862200_B116","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1182\/blood-2009-07-234062","article-title":"Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?","volume":"114","author":"Pullarkat","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111808234862200_B117","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2010.09.003","article-title":"Controversies surrounding iron chelation therapy for MDS.","volume":"25","author":"Leitch","year":"2011","journal-title":"Blood Rev"},{"issue":"5","key":"2019111808234862200_B118","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2141.2007.06695.x","article-title":"Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.","volume":"138","author":"Chacko","year":"2007","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111808234862200_B119","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2141.2011.08749.x","article-title":"Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes.","volume":"154","author":"Roy","year":"2011","journal-title":"Br J Haematol"},{"key":"2019111808234862200_B120","first-page":"2776","article-title":"Impact of iron chelation therapy on overall survival and AML transformation in lower risk MDS patients treated at the Moffitt Cancer Centre [abstract].","volume":"118","author":"Komrokyi","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"8","key":"2019111808234862200_B121","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.leukres.2012.04.006","article-title":"Improved survival in MDS patients receiving iron chelation therapy: a matched pair analysis of 188 patients from the D\u00fcsseldorf MDS registry.","volume":"36","author":"Neukarchen","year":"2012","journal-title":"Leuk Res"},{"issue":"2","key":"2019111808234862200_B122","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1365-2141.1996.d01-1795.x","article-title":"The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload.","volume":"94","author":"Jensen","year":"1996","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111808234862200_B123","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3324\/haematol.2011.048546","article-title":"Hematological responses with deferasirox therapy in transfusion-dependent myelodysplastic syndrome patients.","volume":"97","author":"Gattermann","year":"2012","journal-title":"Haematologica"},{"issue":"2","key":"2019111808234862200_B124","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000158631","article-title":"Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.","volume":"120","author":"Messa","year":"2008","journal-title":"Acta Haematol"},{"issue":"5","key":"2019111808234862200_B125","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.leukres.2010.11.027","article-title":"Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review.","volume":"35","author":"Guariglia","year":"2011","journal-title":"Leuk Res"},{"issue":"17","key":"2019111808234862200_B126","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1200\/JCO.2010.34.1222","article-title":"Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome.","volume":"30","author":"List","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111808234862200_B127","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1152\/jappl.2000.89.2.680","article-title":"Effects of desferrioxamine on serum erythropoietin and ventilatory sensitivity to hypoxia in humans.","volume":"89","author":"Ren","year":"2000","journal-title":"J Appl Physiol"},{"issue":"5516","key":"2019111808234862200_B128","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1059796","article-title":"Targeting of HIF-a to von Hippel-Lindau ubiquitylation complex by O2 regulated prolyl hydroxylation.","volume":"292","author":"Jaakkola","year":"2001","journal-title":"Science"},{"issue":"3","key":"2019111808234862200_B129","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0300-483X(95)03301-U","article-title":"The pharmacokinetics and blood-brain barrier permeation of the chelators 1, 2 diethyl-, and 1 [ethan-1\u2032 01]-2-methyl-3-hydroxypyridin-4-one in the rat.","volume":"108","author":"Fredenburg","year":"1996","journal-title":"Toxicology"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/18\/3657\/1359430\/zh804412003657.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/18\/3657\/1359430\/zh804412003657.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T08:47:45Z","timestamp":1574066865000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/18\/3657\/30692\/How-I-treat-transfusional-iron-overload"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,1]]},"references-count":129,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2012,11,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-05-370098","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,1]]}}}